Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prasugrel Monotherapy Reduced Dose in ACS and CCS Patients After PCI
NCT06916520Phase 4Recruiting
- Start
- Nov 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of prasugrel in coronary artery disease (CAD), acute coronary syndrome (ACS) and Chronic Coronary Syndrome (CCS) (2 arms). Primary endpoint: Net Adverse Clinical Events at 12 months. Started Nov 2025; status: recruiting.
02
Drugs
prasugrel
03
Conditions
coronary artery disease (CAD)acute coronary syndrome (ACS)Chronic Coronary Syndrome (CCS)
Beyond the preview
Go deeper on NCT06916520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06916520.